Kane Biotech (TSE:KNE) has released an update.
Kane Biotech has struck a landmark deal with I-MED Pharma to license its DispersinB® technology globally, promising to boost I-MED’s eye care product line over a five-year period with minimum annual royalties beginning in 2025. This first commercial agreement for DispersinB® positions it as the benchmark for biofilm dispersion technologies in the fight against ocular surface diseases. Kane Biotech specializes in the development of technologies to prevent and remove microbial biofilms, with a significant portfolio of patents and products.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
